Dysplastic Nevus Syndrome

Download PDF

Recent Publications on Dysplastic Nevus Syndrome:
Dermoscopy and suture marking as a tool to enhance diagnosis of pigmented lesions. Melanoma inhibitory activity (MIA) protein was identified in significant...	3rd October, 2008	Ronald O Perelman Department of Dermatology, New York University School of	Dermatol Surg. 2008 Aug;34(8):1104-7. Epub 2008 May 6. DOI Direct Link
Dermoscopy: basic concepts. Dermoscopy is a very useful technique for the analysis of pigmented skin...	1st October, 2008	Sector of Dermatology and Post-Graduation Course in Dermatology,	Int J Dermatol. 2008 Jul;47(7):712-9. DOI Direct Link
Nodal melanocytic nevus with balloon-cell change (nodal balloon-cell nevus). Most nodal nevi are intracapsular and present the morphology of...	20th September, 2008	Dermatopathology Section, Pigmented Skin Lesions, S. M. Annunziata	J Cutan Pathol. 2008 Jul;35(7):672-6. Epub 2008 Feb 29. DOI Direct Link
Increased melanogenesis is a risk factor for oxidative DNA damage--study on cultured melanocytes and atypical nevus cells. Melanin synthesis is an oxygen-dependent process that acts as a potential...	13th September, 2008	Department of Clinical Chemistry, Leiden University Medical Center,	Photochem Photobiol. 2008 May-Jun;84(3):550-5. DOI Direct Link
Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Melanoma inhibitory activity (MIA) protein was identified in significant...	30th August, 2008	Department of Surgery, University Hospital Sestre Milosrdnice,	Melanoma Res. 2008 Jun;18(3):201-7. DOI Direct Link
→View more research publications.

Dysplastic Nevus Syndrome Clinical Trials:
Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome	Melanoma (Skin)

Dysplastic Nevus Syndrome Patents:
US Patent No.	Title
6124303	Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
6232312	Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
6239136	Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
6262059	Method of treating a patient having precancerous lesions with quinazoline derivatives
6268372	Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
→View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Dysplastic Nevus Syndrome scientists - we have details of around 89 individuals working on Dysplastic Nevus Syndrome .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.